We are live on
!
Find out more
ED
Exane Derivatives Portfolio holdings
AUM
$174M
1-Year Est. Return
7.84%
This Fund
S&P 500
This Quarter
Est. Return
-11.28%
1 Year Est. Return
-7.84%
3 Year Est. Return
+42.72%
5 Year Est. Return
+56.28%
10 Year Est. Return
–
AUM
$557M
AUM Growth
+$24M
(+4.5%)
Cap. Flow
+$19M
Cap. Flow
% of AUM
3.41%
Top 10 Holdings %
Top 10 Hldgs %
30.34%
Holding
771
New
78
Increased
167
Reduced
171
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$24M |
| 2 |
iShares MSCI Mexico ETF
EWW
|
+$11.9M |
| 3 |
iShares MSCI Indonesia ETF
EIDO
|
+$8.83M |
| 4 |
Boeing
BA
|
+$6.9M |
| 5 |
BCE
BCE
|
+$4.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBS Group
UBS
|
+$30.9M |
| 2 |
iShares MSCI Taiwan ETF
EWT
|
+$9.78M |
| 3 |
Stellantis
STLA
|
+$8.56M |
| 4 |
Deutsche Bank
DB
|
+$7.5M |
| 5 |
iShares MSCI India ETF
INDA
|
+$5.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 11.37% |
| 2 | Technology | 8.96% |
| 3 | Industrials | 7.17% |
| 4 | Consumer Discretionary | 6.46% |
| 5 | Energy | 5.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
lululemon athletica
LULU
$13.4B
| $39.8K | 0.01% |
327
+326
| +32,600% | +$43.7K |
|
377
BioMarin Pharmaceuticals
BMRN
$11.6B
| $39.8K | 0.01% |
467
+454
| +3,492% | +$43.2K |
|
378
Medtronic
MDT
$108B
| $39.5K | 0.01% |
434
| – | – |
|
|
ARRY
379
DELISTED
Array Biopharma Inc
ARRY
| $39.4K | 0.01% |
+2,763
| New | +$41.9K |
|
380
Stryker
SYK
$129B
| $39.3K | 0.01% |
+251
| New | +$42K |
|
381
Illumina
ILMN
$28.7B
| $39K | 0.01% |
134
+133
| +13,300% | +$41.2K |
|
382
Thermo Fisher Scientific
TMO
$208B
| $38.9K | 0.01% |
+174
| New | +$40.8K |
|
383
Royal Caribbean
RCL
$81.8B
| $38.8K | 0.01% |
397
+386
| +3,509% | +$42.3K |
|
384
Avnet
AVT
$7.25B
| $38.8K | 0.01% |
1,075
| – | – |
|
385
Intuitive Surgical
ISRG
$128B
| $38.8K | 0.01% |
+243
| New | +$41.2K |
|
|
AABA
386
DELISTED
Altaba Inc
AABA
| $38.4K | 0.01% |
663
| – | – |
|
387
Orthofix Medical
OFIX
$481M
| $37.9K | 0.01% |
+723
| New | +$41.1K |
|
|
CLVS
388
DELISTED
Clovis Oncology, Inc.
CLVS
| $37.7K | 0.01% |
2,100
| – | – |
|
389
Marriott Vacations Worldwide
VAC
$3.4B
| $37.6K | 0.01% |
+534
| New | +$44.5K |
|
390
LCI Industries
LCII
$2.52B
| $37.3K | 0.01% |
+558
| New | +$40.7K |
|
391
Snap-on
SNA
$21.1B
| $36.2K | 0.01% |
249
| – | – |
|
392
Encompass Health
EHC
$11.3B
| $35.6K | 0.01% |
+725
| New | +$41.2K |
|
393
Ultragenyx Pharmaceutical
RARE
$2.65B
| $35.6K | 0.01% |
+818
| New | +$44.7K |
|
394
Ligand Pharmaceuticals
LGND
$5.96B
| $35.5K | 0.01% |
+420
| New | +$44.8K |
|
395
PUT
iShares MSCI Brazil ETF
EWZ
$9.08B
| $35.1K | 0.01% |
3,500
| – | – |
|
396
Neurocrine Biosciences
NBIX
$17.7B
| $34.6K | 0.01% |
485
+484
| +48,400% | +$46.4K |
|
|
BLUE
397
DELISTED
bluebird bio
BLUE
| $34.4K | 0.01% |
+27
| New | +$41.4K |
|
398
NextEra Energy
NEE
$185B
| $34.4K | 0.01% |
792
| – | – |
|
399
BBVA Argentina
BBAR
$3.92B
| $34.2K | 0.01% |
3,021
| – | – |
|
400
Eversource Energy
ES
$28.1B
| $34.1K | 0.01% |
524
| – | – |
|
Similar funds
PC
TWMP
LPWM
ACM
HWIS
LWM
EW
GDWAM
Exane Derivatives's Q4 2018 Portfolio in Review
As of Q4 2018, Exane Derivatives held 771 positions worth $557M, up 4.5% from $533M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Exane Derivatives deployed $19M of net new capital in Q4 2018, opening 78 new positions and adding to 167 existing holdings. Its largest new stake was Linde: 152,047 shares worth $24.1M.
By sector, the portfolio is most concentrated in Materials at 11% of assets, up from 6.4% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was iShares MSCI Taiwan ETF, an estimated $9.78M trimmed.
- Exane Derivatives's largest Q4 2018 buy was Linde: 152,047 shares worth $24.1M.
- Exane Derivatives added most to BCE in Q4 2018, an estimated $4.62M increase.
- Exane Derivatives's biggest Q4 2018 reduction was iShares MSCI Taiwan ETF, cutting an estimated $9.78M.
- Exane Derivatives fully exited UBS Group in Q4 2018, selling an estimated $30.9M.
- Exane Derivatives's ten largest holdings make up 30% of its $557M portfolio in Q4 2018.
- Exane Derivatives opened 78 new positions and closed 97 in Q4 2018.
- Exane Derivatives's portfolio value rose 4.5% quarter-over-quarter to $557M.
Based on Exane Derivatives's 13F filing for Q4 2018, filed 31 Jan 2019.